Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., . . . Walsh, T. J. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother.
Citación estilo ChicagoPetraitis, Vidmantas, et al. "Combination Therapy With Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis." Antimicrob Agents Chemother 2020.
Cita MLAPetraitis, Vidmantas, et al. "Combination Therapy With Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis." Antimicrob Agents Chemother 2020.